All In Biotech

Drug Trial Radar · NCT03288493

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

105

Actual

Start

Sep 20, 2017

Primary completion

Apr 27, 2022

Study completion Apr 27, 2022

Sponsor

Lead sponsor
Poseida Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
California Institute for Regenerative Medicine (CIRM)
First posted
Sep 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.

Conditions

  • Multiple Myeloma

Interventions

  • P-BCMA-101 CAR-T cellsBiological

    P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated.

  • RimiducidDrug

    Rimiducid (safety switch activator) may be administered as indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Assess the Safety of P-BCMA-101Time frame: Baseline through Day 28
  2. Phase 1: Maximum Tolerated Dose of P-BCMA-101Time frame: Baseline through Day 28
  3. Phase 2: Assess the Safety of P-BCMA-101Time frame: Baseline through 24 months
  4. Phase 2: Assess the Efficacy of P-BCMA-101 (ORR)Time frame: Baseline through 24 months
  5. Phase 2: Assess the Efficacy of P-BCMA-101 (DOR)Time frame: Baseline through 24 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of California Davis

    Davis, California

  • University of California San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Chicago

    Chicago, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Wayne State - Karmanos Cancer Institute

    Detroit, Michigan

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Swedish Cancer Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.